Aripiprazole Tablet
Product Images NDC 68071-3848

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 68071-3848). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3848 3)

Label for Aripiprazole 5 mg tablets, containing 30 tablets per package, manufactured by NuCare Pharmaceuticals, Inc. The label includes the NDC 68071-3848-3, product number R1912030, and instructions to see the manufacturer's label for the full list of ingredients. It has warnings to keep out of reach of children and to store at controlled temperatures of 68-77°F.*

FDA Label Image

Camber-logo (Camber Logo)

FDA Label Image

Figure1 (Figure1)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing the fold change in aripiprazole concentration (AUC and Cmax) relative to reference without interacting drugs. It includes data for CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blockers famotidine, and other drugs valproate, lithium, and lorazepam, with 90% confidence intervals for each.*

FDA Label Image

Figure2 (Figure2)

A chart showing the effect of various drugs on the pharmacokinetics of Aripiprazole. It presents fold changes with 90% confidence intervals for parameters AUC and Cmax relative to a reference condition without interacting drugs, including CYP3A4 and CYP2D6 inhibitors, inducers, gastric acid blockers, and other drugs like valproate, lithium, and lorazepam.*

FDA Label Image

Figure3 (Figure3)

A scatter plot graph titled 'Effect of Aripiprazole on Other Drugs' showing fold change and 90% confidence intervals for various drugs and pharmacokinetic parameters (AUC and Cmax) relative to a reference without the interacting drug. Drugs listed include dextromethorphan, S- and R-warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. The x-axis represents change relative to reference from 0.5 to 3.0 fold.*

FDA Label Image

Figure4 (Figure4)

A pharmacokinetic chart illustrating Aripiprazole fold change and 90% confidence intervals for special populations. Variables include CYP2D6 metabolizer status, gender, age groups, hepatic and renal impairment, showing changes in AUC and Cmax relative to reference values.*

FDA Label Image

Figure5 (Figure5)

A pharmacokinetic chart depicting the fold change and 90% confidence interval for dehydro-aripiprazole relative to reference values. The chart compares variables such as CYP2D6 metabolism status, gender, age groups, and degrees of hepatic and renal impairment, showing changes in AUC and Cmax levels.*

FDA Label Image

Figure6 (Figure6)

A Kaplan-Meier curve chart showing the proportion of subjects with relapse over days from randomization comparing Aripiprazole and placebo groups. The X-axis represents days from randomization, and the Y-axis shows the proportion with relapse. The chart includes numbers of subjects at risk for both groups at various time points.*

FDA Label Image

Figure7 (Figure7)

A Kaplan-Meier plot showing the proportion of relapse over days from randomization for two groups: Aripiprazole (solid line) and Placebo (dashed line). The x-axis represents days from randomization up to 182 days. The y-axis represents the proportion of subjects with relapse, ranging from 0 to 1. The number of subjects at risk at various time points is listed below the x-axis for each group.*

FDA Label Image

Figure8 (Figure8)

A Kaplan-Meier survival curve graph showing the proportion of subjects with relapse over days from randomization, comparing Aripiprazole to placebo. The x-axis indicates days from randomization (0 to 364), and the y-axis shows the proportion with relapse (0 to 1.0). The number of subjects at risk over time is displayed below the x-axis for both groups.*

FDA Label Image

Figure9 (Figure9)

A line graph showing change in YGTSS total TIC score from baseline over 8 weeks of treatment. The graph compares three groups: Abilify Low, Abilify High, and Placebo, depicting least-squares mean changes with decreasing TIC scores over time for both Abilify treatments, with Placebo showing less reduction.*

FDA Label Image

Structure-1 (Structure 1)

Chemical structure diagram of the active ingredient Aripiprazole, showing its molecular connectivity and arrangement as represented in the illustrative skeletal formula.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.